Dr. Jason Hafron Talks About Developments in Prostate Cancer Testing

Dr. Jason Hafron recently spoke to Targeted Oncology about an important development in prostate cancer testing to help doctors better understand your risk.

There is a blood test for prostate cancer that can help doctors better understand your risk. It’s called IsoPSA. MIU has been using the test since 2018, when the first trials began, and it’s now poised for FDA approval.

The IsoPSA test is more precise than the usual PSA test, meaning it can help avoid unnecessary prostate biopsies for about half of the patients. If your IsoPSA score is low, it means your risk of having serious prostate cancer stays low over time, so you might not need as many follow-up tests. A high score, however, means you’re at higher risk and will need closer attention and a personalized treatment plan. This test is very easy to use. It’s a simple blood-based test.

Read Dr. Hafron’s complete interview here: Long-Term Data Validates IsoPSA for Prostate Cancer Risk Stratification.